Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 10Active not recruiting 9Recruiting 6

Sponsor Class

OTHER 8INDUSTRY 6FED 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 4Dermatologic 1

Conditions

Breast Neoplasms 3Moderate Hepatic Impairment 1Melanoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Healthy Participants 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × capivasertib × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT07343960 2026-05-20

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

AstraZeneca

Phase 1 Recruiting
20 enrolled

Moderate Hepatic Impairment

NCT07287917 2026-05-12

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Aminex Therapeutics, Inc.

Phase 1/2 Recruiting
92 enrolled
BreastDermatologic

Breast Neoplasms, Melanoma

NCT06982521 2026-05-08

ReDiscover-2

Relay Therapeutics, Inc.

Phase 3 Recruiting
540 enrolled
Breast

Breast Neoplasms

NCT07241065 2026-04-15

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

AstraZeneca

Phase 1 Recruiting
42 enrolled

Healthy Participants

NCT05563220 2026-01-06

ELEVATE

Stemline Therapeutics, Inc.

Phase 1/2 Recruiting
435 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡